Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that its first product, the Xenoscope, was 510(k) cleared by the U.S. FDA for marketing and distribution. The Xenoscope is the first single-use disposable laparoscope that will be offered in a sterile condition.
- Trudell Medical Group Makes a Strategic Investment in Xenocor, Developer of the Xenoscope
- MedTech Innovator Unveils Top 50 Medtech Startups Selected for Annual Showcase and Accelerator
- XENOCOR Secures Investment from Growing Impact Ventures
- Mountain Pacific Venture Fund Invests in Laparoscopic Device Company Xenocor
- Xenocor Granted Breakthrough Technology Agreement with Premier Inc.